Shares of IVERIC bio Inc (NASDAQ:ISEE) have been assigned a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong sell rating.
Zacks has also given IVERIC bio an industry rank of 70 out of 256 based on the ratings given to related companies.
Several analysts have recently commented on ISEE shares. Zacks Investment Research lowered shares of IVERIC bio from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine lowered shares of IVERIC bio from a “hold” rating to a “sell” rating in a research report on Wednesday.
IVERIC bio (NASDAQ:ISEE) last issued its earnings results on Tuesday, February 26th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.16). On average, research analysts predict that IVERIC bio will post -1.26 earnings per share for the current fiscal year.
About IVERIC bio
IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).
Featured Article: Catch-Up Contributions
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.